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The optimal approach to surveillance following remission with first line therapy for diffuse 
large B cell lymphoma (DLBCL) remains controversial with a paucity of evidence whether 
follow up is effective in early relapse detection, role of blood tests, optimal frequency and 
duration of follow up, and little data in the modern rituximab era (Cohen, et al 2015).   
There is no guideline consensus. British Society of Haematology guidelines in 2016 
recommend clinical follow up for two years followed by discharge, based on the observation 
that <10% of patients relapse after more than two years (Chaganti, et al 2016).  The 
National Institute of Clinical Excellence (NICE) guidelines in 2016 recommend follow up for 
three years (National Institute of Clinical Excellence). By contrast, the 2014 Lugano 
consensus recommends longer follow up, 3 monthly for 2 years, 6 monthly for 3 years and 
then annual follow up (Cheson, et al 2014).  We have evaluated the approach in our centre 
in the rituximab era with clinical follow up for at least 5 years with routine blood tests 
including lactate dehydrogenase (LDH) without routine imaging.  
 
Patients with DLBCL treated in the Leeds Cancer Centre between 2006-2014 were 
retrospectively identified.  Criteria for inclusion were: age >18 at diagnosis, pathological 
diagnosis of DLBLC, curative intent treatment with rituximab and anthracycline-containing 
chemotherapy, response consistent with remission. Exclusion criteria were: palliative 
treatment including attenuated chemotherapy, transformed indolent lymphoma, 
concurrent low grade lymphoma, CNS disease.  Standard follow up schedule was: clinic 3 
monthly for 1 year, 4 monthly for 1 year, 6 monthly for 3 years, option of discharge or 
annual follow up, with a bloods including LDH at each appointment.  Imaging was not 
routinely performed, although occasionally at clinician discretion.  Relapse was categorised 
as symptomatic (including patient-detected lymph nodes) or asymptomatic (including 
abnormal examination findings not been noticed by the patient).  Methods of relapse 
detection were categorised: patient reported at routine clinic, clinical examination at 
routine clinic (abnormality not reported by patient), detection via routine clinic blood tests, 
early clinic visit, routine imaging, other route (e.g. Accident and Emergency (A&E) 
department attendance, via General Practioner (GP)). 
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185 patients were identified who entered routine follow up.  Patient and treatment 
characteristics are shown in Supplementary Table 1.  Median follow-up was 57.2 months 
(range 5.9-109 months).  Two and five year relapse-free survival and overall survival were 
87.4%, 84.6% and 90.2%, 79.5% respectively. 30/185 (16.2%) of patients relapsed during 
follow up.  7/30 (23%) of relapses were in patients with stage I/IIA disease.  Median time to 
relapse was 16 months post diagnosis. 23/30 relapses (77%) occurred within 24 months of 
diagnosis.  
 
Regarding relapse presentation, 26/30 (87%) were symptomatic at time of relapse. Of these, 
10 presented with pain, 7 with a new patient-detected lump, three with CNS symptoms, and 
one each with lethargy, dyspnoea, ascites, increased sweating, weight loss and a 
dermatological lesion.  Table 1 summarises the method of relapse detection.  10/30 (33%) 
relapses were via self-reports at routine clinic appointments and 8/30 (27%) self-reports 
between clinics (via a telephone call from patients regarding new concerning symptoms, 
prompting unscheduled clinic assessment).  3/30 (10.0%) relapses were identified after a GP 
referral and 5/30 (16.7%) as the result of attendance at an A&E department.  4 patients who 
had a relapse detected were asymptomatic and did not report any concerns.  This included 
two patients had abnormal lymph nodes detected at routine clinic examination.  One 
patient had pancytopenia detected on a routine bloods 12 months post treatment at  follow 
up; this patient had bone marrow disease at presentation.  One patient had relapse 
identified on a CT scan repeated 3 months following post-treatment imaging in view of a 
complete response uncomfirmed.  Overall, 16/30 (53.3%) relapses were identified outside 
routine clinical follow up appointments.  Figure 1 summarises methods of relapse detection. 
 
These data show that this clinically based follow up schedule incorporating regular blood 
monitoring was ineffective at detection of asymptomatic disease recurrence. The pattern of 
the majority of relapses occurred early is consistent with other series (El-Galaly, et al 2015, 
Thompson, et al 2014). A large majority of relapses were detected via symptomatic 
presentation, consistent with reports of clinical follow up programmes pre-rituximab (Elis, et 
al 2002, Weeks, et al 1991).  Despite a frequent schedule of routine clinic visits/blood 
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monitoring, most patients with relapse presented between regular clinic intervals, with a 
majority (53%) of relapses detected via either unscheduled appointments or GP/A&E visits. 
 
Routine blood monitoring led to the detection of relapse in a single asymptomatic patient in 
this series. There were no cases of asymptomatic relapse detection based upon LDH 
elevation.  A study in the pre-rituximab era (Weeks, et al 1991) led to the widespread 
implementation of LDH in routine surveillance.  However, it has been shown that most 
patients with relapse preceded by an LDH elevation also have symptoms (El-Sharkawi, et al 
2012), and that a raised LDH has limited sensitivity (44-69%) and poor positive predictive 
value (9-38%) (Cheah and Seymour 2014).  The lack of utility of routine blood tests, 
including LDH, in our series suggests that routine blood monitoring has little value.   
 
The question of whether it is feasible to detect early asymptomatic recurrence should 
underpin the design of evidence-based follow up programmes. Imaging surveillance is not 
recommended (Cheson, et al 2014); in studies with CT or PET, the majority of relapses were 
identified symptomatically outside of the timeframe of scheduled visits with no survival 
benefit (El-Galaly, et al 2015, Thompson, et al 2014). DLBCL relapse is generally aggressive 
with rapidly developing symptoms. Rapid disease progression translates into a short lead 
time for preclinical diagnosis.  This is reflected in our results with the observation of a very 
high proportion of relapses being symptomatic and often detected at unscheduled visits or 
via other healthcare routes, with the use of routine bloods being ineffective. These data 
suggest that follow up programmes should be reconfigured to improve responsiveness to 
patient reported symptoms.  Long term routine face-to-face clinic follow up of 
asymptomatic patients is of little value, and early discharge with education and rapid clinic 
access for re-evaluation can be recommended.   
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Figures 
 
Figure 1: Pattern of relapse detection over time.  Relapses detected via routine clinic follow 
up (blue) and outside of routine clinic follow up (red). 
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Table 1: Method of relapse detection 
 
 
 
 
 
Method of relapse detection  Overall Relapse within 
2 years of 
diagnosis 
Relapse after 2 
years of 
diagnosis 
Patient self-reporting between routine 
clinics 
8 6 2 
Patient self-reporting at routine clinics 10 7 3 
Clinical examination during routine clinics 2 1 1 
Routine blood tests 1 1 0 
Routine radiological investigations 1 1 0 
GP referral 3 3 0 
A&E admission 5 4 1 
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Supplementary Table 1: Patient, disease, treatment characteristics of patients entering 
routine follow up 
 
 n (total =185) % 
Age (years): 
  Mean 
  Median 
  Range 
 
62 
65 
20 – 91 
 
Sex: 
  Male 
  Female 
 
109 
76 
 
58.9 
41.1 
Stage: 
  Stage IA/IIA: 
      Stage IA 
      Stage IIA 
  Stage IB/IIB/III/IV: 
      Stage IB 
      Stage IIB 
      Stage IIIA/IIIB 
      Stage IVA/IVB 
  B symptoms 
  Extranodal 
 
76 
38 
38 
109 
2 
6 
26 
75 
37 
30 
 
41.1 
20.5 
20.5 
58.9 
1.1 
3.2 
14.1 
40.5 
20.0 
16.2 
 
Treatment regimen: 
  R-CHOP 
  R-CODOX-M/IVAC 
 
179 
6 
 
96.8 
3.2 
All patients: 
  3 x R-CHOP + radiotherapy 
  6-8 x R-CHOP 
  6-8 x R-CHOP + radiotherapy 
  <6 x R-CHOP* 
  R-CODOX-M/IVAC 
 
 
19 
109 
27 
24 
6 
 
10.3 
58.9 
14.6 
13.0 
3.2 
Response assessment: 
  CT 
  PET 
  Other** 
 
131 
46 
8 
 
70.8 
24.9 
4.3 
 
*Planned for 6-8 x R-CHOP but stopped early due to toxicity (8 with stage I/IIA disease). 
**No radiologically assessable disease (either excised at diagnosis or detectable by 
endoscopy only) 
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